



Trial Information Summary

ALLG Trial Number:	MM16
Trial Name: Phase II study assessing the effect of carfilzomib treatment on early free light chain kinetics in myeloma patients with renal impairment	
Lay Summary: The cancer cells in myeloma produce large amounts of small proteins known as light chains that can cause kidney failure. Renal impairment or kidney failure occurs in up to 50% of patients and has been shown to greatly reduce patient survival. Some studies have shown that improving kidney function or how they work in patients with myeloma results in better survival from the disease. The improvement in the function of the kidneys and the response to myeloma therapy can often be seen by the lowering of the light chain measurement. In this study, MM16, patients with newly diagnosed, relapsing or progressive myeloma will be given a new drug, carfilzomib. Carfilzomib works in a similar way to a drug that is already approved for treatment of myeloma, but it is thought that carfilzomib may fight the disease better. The known side effects of the carfilzomib are similar to the other myeloma treatment although not all side effects are yet known. If carfilzomib is fighting the disease well, the patient can stay on the drug for as long as possible. Light chain measurements will be taken soon after carfilzomib is given to see if this early measurement is linked to better kidney function after 4 months of treatment. The study will also determine whether myeloma in patients taking carfilzomib responds to the drug and the length of time until the myeloma progresses.	
Participating Hospitals: 1. Alfred / 2. Calvary Mater Newcastle / 3. Princess Alexandra / 4. Royal Adelaide / 5. Royal Prince Alfred	
Target Accrual (International):	N/A
Target Accrual (ALLG):	36-40
Expected Final Accrual Date:	February 2017